This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hillier, C. Articles by McMurray, J. Search for Related Content PubMed PubMed Citation Articles by Hillier, C. Articles by McMurray, J. Related Collections Other arteriosclerosis Endothelium/vascular type/nitric oxide Other Vascular biology

(Circulation. 2001;103:1378.)
© 2001 American Heart Association, Inc.

Brief Rapid Communications

Effects of Urotensin II in Human Arteries and Veins of Varying Caliber

Chris Hillier, BSc, PhD; Colin Berry, MB, ChB, MRCP; Mark C. Petrie, BSc, MBChB, MRCP; Patrick J. O’Dwyer, MD, FRCS; Carlene Hamilton, BSc, PhD; Amanda Brown, BSc; John McMurray, MD, FRCP, FESC

From the Departments of Medicine and Therapeutics and Surgery, University of Glasgow and Vascular Assessment Group (C.H., A.B.), Caledonian University, Glasgow, UK.

Correspondence to Professor John J.V. McMurray, Wolfson Building, University of Glasgow, United Kingdom G12 8QQ. E-mail j.mcmurray{at}bio.gla.ac.uk

Background—Urotensin II (UII) is the ligand for the GPR14 receptor and the most potent vasoconstrictor in the cynomolgus monkey. UII also contracts rat thoracic aorta. We studied the effect of human UII (hUII) in human blood vessels

Methods and Results—Small subcutaneous resistance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studied using standard techniques. Subcutaneous resistance arteries constricted in response to norepinephrine (maximum tension, 2.84±0.38 mN/mm; the concentration required to produce 50% of the maximum response [EC₅₀], 0.52±0.07 µmol/L) and endothelin-1 (maximum tension, 4.19±0.93 mN/mm; EC₅₀, 1.6±0.1 nmol/L). hUII did not contract these arteries, internal mammary arteries, or either type of vein, but it was a potent vasoconstrictor in rat thoracic aorta (maximum tension, 2.36±0.2 mN/mm; EC₅₀, 1.13±0.36 nmol/L).

Conclusions—hUII has no vasoconstrictor action in human arteries and veins of different sizes and vascular beds. Marked species differences in the actions of UII question its importance in human cardiovascular regulation.

Key Words: peptides • vasoconstriction • arteries • veins

This article has been cited by other articles:

				G. Giebing, M. Tolle, J. Jurgensen, J. Eichhorst, J. Furkert, M. Beyermann, F. Neuschafer-Rube, W. Rosenthal, W. Zidek, M. van der Giet, et al. Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II-Mediated Vasoconstriction Circ. Res., September 30, 2005; 97(7): 707 - 715. [Abstract] [Full Text] [PDF]

				R T Bennett, R D Jones, A H Morice, C F C Smith, and M E Cowen Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries Thorax, May 1, 2004; 59(5): 401 - 407. [Abstract] [Full Text] [PDF]

				M. Lim, S. Honisett, C. D. Sparkes, P. Komesaroff, A. Kompa, and H. Krum Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure Circulation, March 16, 2004; 109(10): 1212 - 1214. [Abstract] [Full Text] [PDF]

				Y. Z. Zhu, Z. J. Wang, Y. C. Zhu, L. Zhang, R. M. E. Oakley, C. W. Chung, K. W. Lim, H. S. Lee, M. L. Ozoux, W. Linz, et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H830 - H836. [Abstract] [Full Text] [PDF]

				A. Y. Zhang, Y.-F. Chen, D. X. Zhang, F.-X. Yi, J. Qi, P. Andrade-Gordon, L. de Garavilla, P.-L. Li, and A.-P. Zou Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney Am J Physiol Renal Physiol, October 1, 2003; 285(4): F792 - F798. [Abstract] [Full Text] [PDF]

				A. Brkovic, A. Hattenberger, E. Kostenis, T. Klabunde, S. Flohr, M. Kurz, S. Bourgault, and A. Fournier Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1200 - 1209. [Abstract] [Full Text] [PDF]

				L. L. Ng, I. Loke, R. J. O'Brien, I. B. Squire, and J. E. Davies Plasma Urotensin in Human Systolic Heart Failure Circulation, December 3, 2002; 106(23): 2877 - 2880. [Abstract] [Full Text] [PDF]

				C. Fisher, M. MacLean, I. Morecroft, A. Seed, F. Johnston, C. Hillier, and J. McMurray Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the Heart? Circulation, July 16, 2002; 106(3): 292 - 295. [Abstract] [Full Text] [PDF]

				I. B Wilkinson, J. T Affolter, S. L de Haas, M Paola Pellegrini, J. Boyd, M. J Winter, R. J Balment, and D. J Webb High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man Cardiovasc Res, February 1, 2002; 53(2): 341 - 347. [Abstract] [Full Text] [PDF]